Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results

Gastroenterology（2022）

引用 27|浏览13

暂无评分

摘要

The SERENE CD study results demonstrate no additional benefit of higher adalimumab induction dosing vs the approved standard induction dosing for treating patients with moderately to severely active Crohn’s disease.

查看译文

关键词

Biologic Agent,Monoclonal Antibody,Inflammatory Bowel Disease,TNF Inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要